Norway· NO-ID_2E12DF15-78D9-4B70-AB90-F79B45FCBFC4
Balversa
A erdafitinib product containing erdafitinib, registered in Norway by Janssen-Cilag International N.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Erdafitinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EN01 (erdafitinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Erdafitinib · ATC L01EN01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of erdafitinib costs, country by country.
Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.55 in France to $621.10 in Switzerland — a ×1128 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Erdafitinib · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$621.10
- FR France$0.55
The record
At a glance
FEST (Norway)- Active substance
- Erdafitinib
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Norway (NO)
- ATC code
- L01EN01
- ATC class
- Erdafitinib
- Defined daily dose
- 9 mg, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_2E12DF15-78D9-4B70-AB90-F79B45FCBFC4
- no_varenummer06634756NOK 117745.8
- gtin7323281006114
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
154 interactions on record for erdafitinib.
Graded by severity as the source publishes them — 56 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Erdafitinib · interactions on record
154 records
- 56 severe
- 98 moderate
Most severe, free to view
- Magnesium carbonateA02AA01severe
- Magnesium oxideA02AA02severe
- Magnesium hydroxideA02AA04severe
- Kombinationen von AluminiumsalzenA02AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Erdafitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBALVERSAJanssen-Cilag International N.V., Beerse
- SwitzerlandBalversa
- FinlandBalversaJanssen Cilag International
- FranceBALVERSA 4 mg, comprimés pelliculésJANSSEN CILAG INTERNATIONAL NV
- IrelandBalversa 4 mg Film-coated tabletJanssen-Cilag International NV
- IcelandBalversaJanssen-Cilag International NV*
- NetherlandsBalversa 4 mg filmomhulde tablettenJanssen-Cilag International NV
- PolandBalversaJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Balversa
- Liechtenstein · Balversa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bcf31bfb-d450-4f4c-b73b-a58b90565e4b GET /v1/drugs/bcf31bfb-d450-4f4c-b73b-a58b90565e4b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Erdafitinib",
"merkevare_id": "ID_2E12DF15-78D9-4B70-AB90-F79B45FCBFC4",
"name_form_strength": "Balversa tab 4 mg",
"prescription_group": "C"
}See everything about erdafitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.